Vaccinex Inc. [NASDAQ: VCNX] closed the trading session at $2.35 on 12/08/20. The day’s price range saw the stock hit a low of $2.05, while the highest price level was $2.45. The company report on November 13, 2020 that Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update.
Additional data from SIGNAL Huntington’s disease (HD) trial support continued development in HD and in Alzheimer’s disease (AD).
Phase 1/2 Study to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for H1 2021.
The stocks have a year to date performance of -51.55 percent and weekly performance of 12.98 percent. The stock has been moved at -35.44 percent over the last six months. The stock has performed 34.29 percent around the most recent 30 days and changed -54.81 percent over the most recent 3-months.
If compared to the average trading volume of 1.18M shares, VCNX reached to a volume of 1457800 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Vaccinex Inc. [VCNX]:
BTIG Research have made an estimate for Vaccinex Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 23, 2020. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on September 04, 2018, representing the official price target for Vaccinex Inc. stock.
The Average True Range (ATR) for Vaccinex Inc. is set at 0.18, with the Price to Sales ratio for VCNX stock in the period of the last 12 months amounting to 86.48.
VCNX stock trade performance evaluation
Vaccinex Inc. [VCNX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.98. With this latest performance, VCNX shares gained by 34.29% in over the last four-week period, additionally sinking by -35.44% over the last 6 months – not to mention a drop of -51.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VCNX stock in for the last two-week period is set at 65.02, with the RSI for the last a single of trading hit 72.60, and the three-weeks RSI is set at 53.89 for Vaccinex Inc. [VCNX]. The present Moving Average for the last 50 days of trading for this stock 1.94, while it was recorded at 2.14 for the last single week of trading, and 3.88 for the last 200 days.
Vaccinex Inc. [VCNX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Vaccinex Inc. [VCNX] shares currently have an operating margin of -6121.41 and a Gross Margin at +14.34. Vaccinex Inc.’s Net Margin is presently recorded at -6092.35.
Reflecting on the efficiency of the workforce at the company, Vaccinex Inc. [VCNX] managed to generate an average of -$650,265 per employee. Receivables Turnover for the company is 0.68 with a Total Asset Turnover recorded at a value of 0.04.Vaccinex Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.30.
Earnings per share (EPS) analysis for Vaccinex Inc. [VCNX] stock
With the latest financial reports released by the company, Vaccinex Inc. posted -0.38/share EPS, while the average EPS was predicted by analysts to be reported at -0.58/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 34.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VCNX.
Vaccinex Inc. [VCNX]: Insider Ownership positions
There are presently around $1 million, or 50.30% of VCNX stock, in the hands of institutional investors. The top three institutional holders of VCNX stocks are: VANGUARD GROUP INC with ownership of 142,297, which is approximately 2.892% of the company’s market cap and around 2.20% of the total institutional ownership; TELEMETRY INVESTMENTS, L.L.C., holding 58,300 shares of the stock with an approximate value of $0.14 million in VCNX stocks shares; and CITADEL ADVISORS LLC, currently with $0.11 million in VCNX stock with ownership of nearly New of the company’s market capitalization.
Positions in Vaccinex Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 17 institutional holders increased their position in Vaccinex Inc. [NASDAQ:VCNX] by around 245,817 shares. Additionally, 8 investors decreased positions by around 983,488 shares, while 1 investors held positions by with 787,365 shares. The mentioned changes placed institutional holdings at 441,940 shares, according to the latest SEC report filing. VCNX stock had 9 new institutional investments in for a total of 227,279 shares, while 7 institutional investors sold positions of 971,680 shares during the same period.